RxDoctor Payments DataLook up a doctor →

Teng Moua, MD

Pulmonary Disease · Rochester, MNNPI 1679524227

Payments from drug & device makers

$2,373,167in general payments, 2019–2025

Across 461 payments — averaging $5147.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1.6M
  • United Therapeutics Corporation$769K
  • Boehringer Ingelheim International GmbH$25K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$11K
  • Boehringer Ingelheim France S.a.s.$10K
  • Boehringer Ingelheim Limited$3K

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,373,167 in reported general payments places this provider in the 95th percentile of 261 pulmonary disease providers in Minnesota.

See all pulmonary disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$20,680
Medicare patients
143
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →